ImmunoGen, Inc. Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 16, 2005


ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)


 
Massachusetts
0-17999
04-2726691
  
 
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
  


128 Sidney Street, Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)


Registrant's telephone number, including area code: (617) 995-2500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
ITEM 8.01 - OTHER EVENTS

On November 16, 2005, ImmunoGen, Inc. (Nasdaq: IMGN) issued a press release to announced the presentation of encouraging clinical findings with the Company’s huN901-DM1 Tumor-Activated Prodrug (TAP) compound at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics underway in Philadelphia, PA. Clinical activity seen with huN901-DM1 in this study includes a complete remission lasting at least 15 weeks and stable disease lasting up to 18 weeks.


A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.




ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No.
  
Exhibit
     
99.1
  
Press Release of ImmunoGen, Inc. dated November 16, 2005





 
2
 
 



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
ImmunoGen, Inc.
 
(Registrant)
   
Date: November 16, 2005
/s/ Karleen M. Oberton
   
 
Karleen M. Oberton
 
Senior Corporate Controller
 
(Principal Accounting Officer)
 
 

 
 
3